Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Intra-Abdominal and Abdominal Wall Desmoid Fibromatosis

Intra-Abdominal and Abdominal Wall Desmoid Fibromatosis Desmoid fibromatosis is a rare but locally aggressive tumor comprised of myofibroblasts. Desmoids do not have the ability to metastasize but can cause significant morbidity and mortality by local invasion. These tumors may occur throughout the body, but are commonly found on the abdominal wall and within the intestinal mesentery. Desmoids in these areas may cause unique clinical problems for physicians and patients. Mutations in either the β-catenin or the APC genes are usually the cause for the development of these tumors with the former comprising the sporadic development of tumors and the latter being associated with familial adenomatous polyposis syndrome. Surgical resection with histologically negative margins has been the cornerstone of therapy for this disease, but this paradigm has begun to shift. It is now common to accept a microscopically positive margin after resection as recurrence rates may not be significantly affected. An even more radical evolution in management has been the recent movement towards “watchful waiting” when new desmoids are diagnosed. As the natural history of desmoids has become better understood, it is evident that some tumors will not grow and may even spontaneously regress sparing patients the morbidity of more aggressive therapy. Other modalities of treatment for desmoids include radiation and systemic therapy which both can be used adjuvantly or as definitive therapy and have shown durable response rates as single therapy regimens. The decision to use radiation and/or systemic therapies is often based on tumor biology, tumor location, surgical morbidity, and patient preference. Systemic therapy options have increased to include hormonal therapies, non-steroidal anti-inflammatory drugs and chemotherapy, as well as targeted therapies. Unfortunately, the rarity of this disease has resulted in a scarcity of randomized trials to evaluate any of these therapies emphasizing the need for this disease to be treated at high volume multidisciplinary institutions. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Intra-Abdominal and Abdominal Wall Desmoid Fibromatosis

Howard, J.; Pollock, Raphael
Oncology and Therapy , Volume 4 (1) – Feb 3, 2016
Download PDF
16 pages

Loading next page...
 
/lp/springer-journals/intra-abdominal-and-abdominal-wall-desmoid-fibromatosis-8SJJ6gFax4
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0017-z
Publisher site
See Article on Publisher Site

Abstract

Desmoid fibromatosis is a rare but locally aggressive tumor comprised of myofibroblasts. Desmoids do not have the ability to metastasize but can cause significant morbidity and mortality by local invasion. These tumors may occur throughout the body, but are commonly found on the abdominal wall and within the intestinal mesentery. Desmoids in these areas may cause unique clinical problems for physicians and patients. Mutations in either the β-catenin or the APC genes are usually the cause for the development of these tumors with the former comprising the sporadic development of tumors and the latter being associated with familial adenomatous polyposis syndrome. Surgical resection with histologically negative margins has been the cornerstone of therapy for this disease, but this paradigm has begun to shift. It is now common to accept a microscopically positive margin after resection as recurrence rates may not be significantly affected. An even more radical evolution in management has been the recent movement towards “watchful waiting” when new desmoids are diagnosed. As the natural history of desmoids has become better understood, it is evident that some tumors will not grow and may even spontaneously regress sparing patients the morbidity of more aggressive therapy. Other modalities of treatment for desmoids include radiation and systemic therapy which both can be used adjuvantly or as definitive therapy and have shown durable response rates as single therapy regimens. The decision to use radiation and/or systemic therapies is often based on tumor biology, tumor location, surgical morbidity, and patient preference. Systemic therapy options have increased to include hormonal therapies, non-steroidal anti-inflammatory drugs and chemotherapy, as well as targeted therapies. Unfortunately, the rarity of this disease has resulted in a scarcity of randomized trials to evaluate any of these therapies emphasizing the need for this disease to be treated at high volume multidisciplinary institutions.

Journal

Oncology and Therapy – Springer Journals

Published: Feb 3, 2016

References

  • Abdominal desmoid tumors
    Sakorafas, GH; Nissotakis, C; Peros, G
  • Desmoids in familial adenomatous polyposis
    Clark, SK; Phillips, RK
  • Desmoid tumors: need for an individualized approach
    Bree, E; Keus, R; Melissas, J; Tsiftsis, D; Coevorden, F
  • Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals’ expertise–a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative
    Kasper, B; Baumgarten, C; Bonvalot, S
  • Extra-abdominal desmoid fibromatosis–a sarcoma unit review of practice, long term recurrence rates and survival
    Eastley, N; Aujla, R; Silk, R
  • Desmoid: the role of local therapy in an era of systemic options
    Walczak, BE; Rose, PS
  • A desmoid tumor-staging system separates patients with intra-abdominal, familial adenomatous polyposis-associated desmoid disease by behavior and prognosis
    Church, J; Lynch, C; Neary, P; LaGuardia, L; Elayi, E
  • Recurrence and prognostic factors in patients with aggressive fibromatosis. The role of radical surgery and its limitations
    Bertani, E; Testori, A; Chiappa, A
  • Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm–a position paper from the Italian and the French Sarcoma Group
    Gronchi, A; Colombo, C; Pechoux, C
  • Estrogen receptor-beta expression in extra abdominal fibromatoses: an analysis of 40 cases
    Deyrup, AT; Tretiakova, M; Montag, AG
  • Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk
    Fiore, M; Coppola, S; Cannell, AJ
  • Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients
    Peng, PD; Hyder, O; Mavros, MN
  • A prognostic nomogram for prediction of recurrence in desmoid fibromatosis
    Crago, AM; Denton, B; Salas, S
  • Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation
    Salas, S; Dufresne, A; Bui, B
  • Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution
    Gronchi, A; Casali, PG; Mariani, L
  • Prognostic factors influencing event-free survival and treatments in desmoid-type fibromatosis: analysis from a large institution
    Huang, K; Wang, CM; Chen, JG
  • Optimizing treatment of desmoid tumors
    Lev, D; Kotilingam, D; Wei, C
  • Gene expression profiling of desmoid tumors by cDNA microarrays and correlation with progression-free survival
    Salas, S; Brulard, C; Terrier, P
  • Analysis of APC/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis
    Jilong, Y; Jian, W; Xiaoyan, Z; Xiaoqiu, L; Xiongzeng, Z
  • The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors)
    Lips, DJ; Barker, N; Clevers, H; Hennipman, A
  • CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study
    Colombo, C; Miceli, R; Lazar, AJ
  • Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis
    Crago, AM; Chmielecki, J; Rosenberg, M
  • High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management
    Domont, J; Salas, S; Lacroix, L
  • β-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis
    Huss, S; Nehles, J; Binot, E
  • Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors
    Lazar, AJ; Tuvin, D; Hajibashi, S
  • β-Catenin mutation status and outcomes in sporadic desmoid tumors
    Mullen, JT; DeLaney, TF; Rosenberg, AE
  • Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis
    Broekhoven, DL; Verhoef, C; Grunhagen, DJ
  • Desmoid tumour in familial adenomatous polyposis patients: responses to treatments
    Desurmont, T; Lefevre, JH; Shields, C; Colas, C; Tiret, E; Parc, Y
  • Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution
    Huang, K; Fu, H; Shi, YQ; Zhou, Y; Du, CY
  • Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series
    Mullen, JT; Delaney, TF; Kobayashi, WK
  • The surgical management of soft tissue tumours arising in the abdominal wall
    Pencavel, T; Strauss, DC; Thomas, JM; Hayes, AJ
  • Surgical outcomes following resection for sporadic abdominal wall fibromatosis
    Wilkinson, MJ; Chan, KE; Hayes, AJ; Strauss, DC
  • Surgical resection for non-familial adenomatous polyposis-related intra-abdominal fibromatosis
    Wilkinson, MJ; Fitzgerald, JE; Thomas, JM; Hayes, AJ; Strauss, DC
  • A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis
    Latchford, AR; Sturt, NJ; Neale, K; Rogers, PA; Phillips, RK
  • Intestinal transplantation for the treatment of desmoid tumors associated with familial adenomatous polyposis
    Chatzipetrou, MA; Tzakis, AG; Pinna, AD
  • Modified multivisceral transplantation without a liver graft for Gardner/desmoid syndrome and chronic intestinal pseudo-obstruction
    Jovine, E; Masetti, M; Cautero, N
  • Multivisceral transplantation for the treatment of intra-abdominal tumors
    Nikeghbalian, S; Aliakbarian, M; Shamsaeefar, A; Kazemi, K; Bahreini, A; Malekhosseini, SA
  • Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients
    Bonvalot, S; Eldweny, H; Haddad, V
  • Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment
    Fiore, M; Rimareix, F; Mariani, L
  • Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles
    Nuyttens, JJ; Rust, PF; Thomas, CR; Turrisi, AT
  • Radiation therapy in the management of desmoid tumors
    Ballo, MT; Zagars, GK; Pollack, A
  • Long-term outcomes for desmoid tumors treated with radiation therapy
    Guadagnolo, BA; Zagars, GK; Ballo, MT
  • Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis–an EORTC STBSG and ROG study (EORTC 62991-22998)
    Keus, RB; Nout, RA; Blay, JY
  • Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national patterns of care study
    Micke, O; Seegenschmiedt, MH
  • Role of radiotherapy in the management of desmoid tumors
    Gluck, I; Griffith, KA; Biermann, JS; Feng, FY; Lucas, DR; Ben-Josef, E
  • Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis
    Broekhoven, DL; Verhoef, C; Elias, SG
  • Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)
    Camargo, VP; Keohan, ML; D’Adamo, DR
  • High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors
    Hansmann, A; Adolph, C; Vogel, T; Unger, A; Moeslein, G
  • Regression of sporadic intra-abdominal desmoid tumour following administration of non-steroidal anti-inflammatory drug
    Tanaka, K; Yoshikawa, R; Yanagi, H
  • Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review
    Bocale, D; Rotelli, MT; Cavallini, A; Altomare, DF
  • Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients
    Quast, DR; Schneider, R; Burdzik, E; Hoppe, S; Möslein, G
  • Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis
    Gega, M; Yanagi, H; Yoshikawa, R
  • Combination chemotherapy for desmoid tumors
    Okuno, SH; Edmonson, JH
  • Combination chemotherapy in adult desmoid tumors
    Patel, SR; Evans, HL; Benjamin, RS
  • Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG)
    Garbay, D; Cesne, A; Penel, N
  • Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis
    Azzarelli, A; Gronchi, A; Bertulli, R
  • Multimodality treatment of mesenteric desmoid tumours
    Bertagnolli, MM; Morgan, JA; Fletcher, CD
  • Therapy of desmoid tumors and fibromatosis using vinorelbine
    Weiss, AJ; Horowitz, S; Lackman, RD
  • Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial
    Chugh, R; Wathen, JK; Patel, SR
  • Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)
    Heinrich, MC; McArthur, GA; Demetri, GD
  • Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up
    Penel, N; Cesne, A; Bui, BN
  • A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis
    Jo, JC; Hong, YS; Kim, KP
  • Activity of Sorafenib against desmoid tumor/deep fibromatosis
    Gounder, MM; Lefkowitz, RA; Keohan, ML
  • Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis
    Martin-Liberal, J; Benson, C; McCarty, H; Thway, K; Messiou, C; Judson, I
  • Targeting the Notch pathway: a potential therapeutic approach for desmoid tumors
    Shang, H; Braggio, D; Lee, YJ
  • A Phase I, dose-finding study in patients with advanced solid malignancies of the oral gamma-secretase inhibitor PF-03084014
    Messersmith, WA; Shapiro, GI; Cleary, JM
  • New, tolerable gamma-secretase inhibitor takes desmoid down a notch
    Hughes, DP; Kummar, S; Lazar, AJ
  • Antitumor effects of hyaluronan inhibition in desmoid tumors
    Briggs, A; Rosenberg, L; Buie, JD; Rizvi, H; Bertagnolli, MM; Cho, NL